Securities Law Firm Investigating Shareholder Claims Due to Micrus Buyout
12 Julho 2010 - 3:07PM
Business Wire
Goldfarb Branham LLP is investigating Micrus Endovascular’s
Board of Directors (NASDAQ: MEND) due to the recent merger they
approved with Johnson & Johnson for a 5.5% premium. Micrus
shareholders are encouraged to contact attorney Hamilton Lindley at
877-583-2855 or by email hlindley@goldfarbbranham.com for details
about their rights.
“If the transaction closes, Micrus investors will be cashed out
at $23.40 per share,” stated shareholder lawyer Hamilton Lindley.
“Micrus may not have adequately shopped itself before entering into
this transaction, and Johnson & Johnson may be underpaying for
Micrus, thus unlawfully harming Micrus shareholders.”
If you own Micrus stock and you wish to discuss this matter with
an experienced shareholder attorney, please contact Hamilton
Lindley at 877-583-2855 or by email at
hlindley@goldfarbbranham.com. Goldfarb Branham LLP lawyers have
excellent experience representing shareholders in buyout cases
nationwide. The firm provides nimble, creative and effective
counsel at all stages of litigation.
Micrus Endovascular (MM) (NASDAQ:MEND)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Micrus Endovascular (MM) (NASDAQ:MEND)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
Notícias em tempo-real sobre Micrus Endovascular (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Goldfarb Branham LLP